London, 10, June 2022, BenevolentAI (Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, today announces that it will participate in the following investor conferences:
- Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, CA from June 13 - June 16, 2022
- Morgan Stanley, Putting the Tech in Biotech Conference, Exploring the World of Tech-Enabled Drug Development, in New York, on June 28, 2022
About BenevolentAI
BenevolentAI is a leading, clinical-stage AI drug discovery company. Through the combined capabilities of its AI Platform, scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. BenevolentAI has a consistently proven track record of scientifically validated discoveries. The BenevolentAI Platform™ powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains successful commercial collaborations with leading pharmaceutical companies. BenevolentAI also identified Eli Lilly's baricitinib as a repurposing drug candidate for COVID-19, which has been authorised for emergency use by the FDA. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
Investors
Fleur Wood - Investor Relations
investors@benevolent.ai
Media
Rajin Kang - VP Communications
press@benevolent.ai
Back to press releases and in the media
